Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.5352W HIGH $9.62
Volume
332.55 K
Value Traded
1.43 M
Short % Float
9.32%
+1.9%Week
-11.31%1 Month
-26.6%3 Month
-3.6%6 Month
-97.67%5 Year
-98.66%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
177.48 M
EPS (TTM)
-1.91
P/E Ratio
-
Ent. Value
89.93 M
Total Shares
27.60 M
Float Shares
23.86 M
Insiders
13.55%
Institutions
66.67%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
DTIL Catalyst Timeline
Dated clinical, regulatory and corporate events for Precision BioSciences, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Precision BioSciences, Inc.
419Total events
14Upcoming
80Tier-1 (high impact)
2019 to 2026Coverage
Upcoming catalysts 2
Event history 50
●Enrollment UpdatePBGENE-HBVTrial
Expanding cohorts 4 and 5 in ELIMINATE-B
chronic hepatitis Bsource ↗
▲Trial InitiationPBGENE-DMDTrial
Two clinical trial sites active for FUNCTION-DMD
Duchenne muscular dystrophysource ↗
●Enrollment UpdatePBGENE-DMDTrial
FUNCTION-DMD actively recruiting patients
Duchenne muscular dystrophysource ↗
▲FDA Feedback ReceivedECUR-506FDA Meeting
FDA alignment on key study elements for ECUR-506
ornithine transcarbamylase deficiencysource ↗
▲FDA Feedback Receivedazer-celFDA Meeting
FDA written guidance on registrational pathway for azer-cel
diffuse large B-cell lymphomasource ↗
▲First Patient DosedPBGENE-DMDTrial
First patient dosed in Phase 1/2 FUNCTION-DMD study
Duchenne muscular dystrophysource ↗
◆Late-BreakerPBGENE-HBVPresentation
Late-breaking poster presentation of new clinical biopsy data at EASL Congress 2026
chronic hepatitis Bsource ↗
▲Full ResultsPBGENE-HBVClinical Data
Liver biopsy data showing 1-log reduction in cccDNA transcripts and polymerase inactivation
chronic hepatitis Bsource ↗
▲Biomarker DataPBGENE-HBVClinical Data
First clinical biopsy evidence of direct cccDNA elimination
chronic hepatitis Bsource ↗
▲Safety Data UpdatePBGENE-HBVClinical Data
Safety data: no DLTs, manageable profile with mitigation protocol for hypotension
chronic hepatitis Bsource ↗
▲Topline ReadoutPBGENE-HBVClinical Data
First clinical biopsy evidence of cccDNA elimination
chronic hepatitis Bsource ↗
◆Late-BreakerPBGENE-HBVPresentation
Late-breaking PBGENE-HBV data from ELIMINATE-B trial presented at EASL 2026
chronic hepatitis Bsource ↗
◆Oral PresentationPBGENE-HBVPresentation
Investor webcast to discuss late-breaking PBGENE-HBV data from ELIMINATE-B trial
chronic hepatitis Bsource ↗
▲Preclinical PoCPBGENE-DMDPreclinical
New preclinical data presented at ASGCT 2026 supporting advancement of PBGENE-DMD into clinic
Duchenne muscular dystrophysource ↗
◆Oral PresentationPBGENE-DMDPresentation
Oral presentation of PBGENE-DMD preclinical data at ASGCT 2026
Duchenne muscular dystrophysource ↗
▲Oral PresentationPBGENE-DMDPresentation
Preclinical data presented at ASGCT 2026
Duchenne muscular dystrophysource ↗
▲Oral PresentationECUR-506Presentation
Clinical data presented at ASGCT Annual Meeting
ornithine transcarbamylase deficiencysource ↗
▲Poster PresentationECUR-506Presentation
Poster at SIMD Annual Meeting with one-year data
ornithine transcarbamylase deficiencysource ↗
▲First Patient DosedPBGENE-DMDTrial
First clinical trial site activated and patient screening/enrollment opened for PBGENE-DMD in FUNCTION-DMD study
Duchenne muscular dystrophysource ↗
▲Grant / FundingCorporate
Compensation Committee approved grant of 7,094 RSUs to new employee under Inducement Award Plan
▲Trial InitiationTrial
Clinical trial application approved in two European countries for ELIMINATE-B trial
Hepatitis Bsource ↗
●Oral PresentationPresentation
Precision BioSciences to participate in 25th Annual Needham Virtual Healthcare Conference
▲Milestone Paymentazer-celCorporate
Received $7.5 million clinical milestone payment from TG Therapeutics
multiple sclerosissource ↗
◆Oral PresentationPBGENE-DMDPresentation
Virtual KOL investor event on PBGENE-DMD and FUNCTION-DMD trial
Duchenne muscular dystrophysource ↗
●R&D DayPBGENE-DMDPresentation
KOL event to discuss PBGENE-DMD and FUNCTION-DMD trial
Duchenne muscular dystrophysource ↗
●Enrollment UpdatePBGENE-HBVTrial
13 patients dosed across first 5 cohorts
chronic hepatitis Bsource ↗
▲Fast Track DesignationPBGENE-DMDDesignation
FDA grants Fast Track designation for PBGENE-DMD
Duchenne muscular dystrophysource ↗
◆Poster PresentationPBGENE-DMDPresentation
Poster presentation of preclinical data for PBGENE-DMD at MDA Clinical & Scientific Conference
Duchenne muscular dystrophysource ↗
▲Milestone Paymentazer-celCorporate
Clinical milestone achieved for azer-cel in progressive MS triggers $7.5M payment
progressive multiple sclerosissource ↗
◆R&D DayPBGENE-DMDPresentation
Virtual investor event in March 2026 discussing PBGENE-DMD program
Duchenne muscular dystrophysource ↗
▲Milestone Paymentazer-celCorporate
Precision earned $7.5 million milestone from TG Therapeutics
progressive multiple sclerosissource ↗
▲Patent GrantedPBGENE-HBVIP / Competition
Two Notices of Allowance from USPTO for PBGENE-HBV patents
chronic hepatitis Bsource ↗
▲Fast Track DesignationPBGENE-DMDDesignation
Fast Track designation granted by FDA
Duchenne muscular dystrophysource ↗
▲PRV GrantedPBGENE-DMDDesignation
Eligible for Priority Review Voucher via Rare Pediatric Disease program
Duchenne muscular dystrophysource ↗
▲Fast Track DesignationPBGENE-DMDDesignation
Fast Track designation granted by FDA
Duchenne muscular dystrophysource ↗
▲IND ClearancePBGENE-DMDIND
IND clearance received from FDA for PBGENE-DMD
Duchenne muscular dystrophysource ↗
◆Timing GuidancePBGENE-HBVPresentation
Phase 1 clinical data readout expected
chronic hepatitis Bsource ↗
◆Trial InitiationPBGENE-DMDTrial
First clinical site activation expected in first half of 2026
Duchenne muscular dystrophysource ↗
◆Timing GuidancePBGENE-PMMPresentation
Phase 1 clinical data readout expected
primary mitochondrial myopathysource ↗
◆Oral PresentationPBGENE-HBVPresentation
Late-breaking oral presentation at the Liver Meeting 2025 (AASLD) featuring new data from multiple cohorts of ELIMINATE-B trial
chronic hepatitis Bsource ↗
▲Late-BreakerPBGENE-HBVPresentation
Late Breaker presentation at AASLD The Liver Meeting 2025 showing safety, tolerability and cumulative, dose-dependent antiviral activity
chronic hepatitis Bsource ↗
Past FDA Catalysts and PDUFA Decisions
How DTIL actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | ECUR-506 | Phase 1/2 data readout | Phase 1/2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D35 / 100
Pipeline Score
$4M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.0x
rNPV / MCap
Top 53%
Micro Cap(rank 349 of 658)
Percentile Rank
Precision BioSciences, Inc. faces pipeline headwinds (35/100), with $49M risk-adjusted pipeline value, led by PBGENE-DMD in Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PBGENE-DMD Monoclonal antibodyNCT07429240 | Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD | Phase 1 | RECRUITING | 18 | Dec 1, 2029 |
Clinical Trial Results
Readouts, endpoints and source filings for every DTIL program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| PBGENE-HBV Fast Track | chronic hepatitis B | 2026-05-27 | 1-log (10-fold) reduction in cccDNA-derived transcripts; 100% of patients with detectable pgRNA at baseline achieved pgRNA lossRead More | Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Frankel StanleyDirector | Buy | 1,000 41,478 held | $6.00 | 09/28/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in DTIL
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Octagon Capital Advisors LP | 1 % (-28.6 %) | 10.61 M | 1.35 M | -39.64% ( -886.73 K) |
DTIL Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How DTIL ranks across every disease it competes in
Competitive Position is a premium feature
See how DTIL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialDTIL News
DTIL▲ +2.9%today
Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2026
Precision BioSciences has announced its selection for a late-breaking oral presentation at The Liver Meeting 2026. This prestigious event, organized by the American Association for the Study of Liver Diseases, will occur from November 5-9 in Denver. The presentation will focus on their PBGENE-HBV program, showcasing their ARCUS® gene editing technology.
Read more →DTILPrecision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study
Precision BioSciences has initiated dosing in its Phase 1/2 FUNCTION-DMD clinical trial, focusing on PBGENE-DMD for Duchenne muscular dystrophy. This program aims to address a significant unmet medical need in the treatment of DMD. The trial marks a critical step in evaluating the efficacy of their gene editing therapy.
Read more →DTILPrecision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Precision BioSciences reported its second quarter financial results for 2026, highlighting a significant milestone in the hepatitis B field with the first clinical biopsy evidence supporting its therapeutic approach. The company continues to advance its proprietary ARCUS platform for gene editing therapies targeting high unmet medical needs. Overall, the financial performance reflects positive growth and progress in its clinical initiatives.
Read more →DTILPrecision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026
Precision BioSciences, Inc. has announced it will report its financial results for the second quarter of 2026 on August 6, 2026. The company is focused on developing in vivo gene editing therapies using its proprietary ARCUS® platform. This announcement reflects the company's commitment to transparency and ongoing business operations.
Read more →DTILPrecision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones
Precision BioSciences has announced significant changes to its senior leadership team to enhance the advancement of its clinical programs. Alex Kelly has been promoted to Chief Operating Officer, a new role aimed at overseeing customer-facing functions. These changes are intended to support the company's strategic goals and address high unmet medical needs.
Read more →DTILPrecision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Precision BioSciences has announced the approval of inducement awards for new employees under its 2021 Employment Inducement Incentive Award Plan. This decision, made by the Compensation Committee of the Board of Directors, reflects the company's commitment to attracting talent as it continues to develop its ARCUS platform for gene editing therapies.
Read more →DTIL▲ +8.6%on this news
Precision BioSciences Announces Inclusion in the Russell 2000® Index Expanding Market Visibility with Institutional Investors
Precision BioSciences has been included in the Russell 2000® Index, which is expected to enhance its market visibility and attract institutional investors. This inclusion reflects the company's growth and stability in the biopharma sector. The move is anticipated to bolster investor confidence and expand the company's reach.
Read more →DTILPrecision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026
Precision BioSciences has announced new and late-breaking clinical data from the PBGENE-HBV study during the European Association for the Study of the Liver Congress 2026. The details of the data and its implications for HBV treatment were highlighted, although specifics were not provided in the announcement.
Read more →DTILPrecision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026
Precision BioSciences is set to host an investor webcast to discuss the late-breaking data from the PBGENE-HBV trial presented at the European Association for the Study of the Liver Congress 2026. This event will provide insights into the findings and implications of the trial results for stakeholders. Further details about the webcast will be shared as the event approaches.
Read more →DTILPrecision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting
Precision BioSciences has presented new preclinical data for PBGENE-DMD at the American Society of Gene & Cell Therapy 2026 Annual Meeting. This advancement supports the transition of the therapy into clinical trials. The presentation highlights the company's ongoing commitment to developing innovative gene therapies.
Read more →DTILPrecision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update
Precision BioSciences has reported its financial results for the first quarter of 2026. The company also provided a business update, although specific details regarding performance or future plans were not disclosed in the article. The report appears to be standard for quarterly financial disclosures.
Read more →DTILPrecision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026
Precision BioSciences, Inc. has announced it will report its financial results for the first quarter of 2026 on May 5, 2026. The company is known for its proprietary ARCUS gene editing platform, which aims to develop therapies for genetic and infectious diseases. This announcement comes as the company continues to work on its clinical stage candidates.
Read more →DTILPrecision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study
Precision BioSciences has activated the first clinical trial site for its PBGENE-DMD treatment aimed at Duchenne muscular dystrophy (DMD). The Phase 1/2 FUNCTION-DMD study will evaluate the safety, tolerability, and efficacy of this novel gene editing therapy. Patient enrollment has commenced at Arkansas Children's Hospital, which is recognized for its specialized care in DMD.
Read more →DTILPrecision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting
Precision BioSciences announced that new preclinical data from its PBGENE-DMD program will be presented at the ASGCT 2026 Annual Meeting. The data highlights the efficacy of PBGENE-DMD in early-juvenile mice, suggesting potential benefits for younger patients with Duchenne muscular dystrophy. The program aims to improve function in about 60% of DMD patients and has received FDA designations to expedite its development.
Read more →DTIL▲ +6.3%on this newsshared move
Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026
Precision BioSciences announced a late-breaking poster presentation for PBGENE-HBV at the EASL Congress 2026, showcasing new clinical biopsy data from the Phase 1 ELIMINATE-B trial. This trial evaluates PBGENE-HBV as a treatment for chronic hepatitis B, aiming to eliminate cccDNA, the root cause of the infection. The program has received Fast Track designation from the FDA, highlighting its potential as a curative therapy.
Read more →DTIL▲ +5.9%on this news
Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries
Precision BioSciences has received approval for its ELIMINATE-B trial in two European countries. This expansion allows for broader patient enrollment and enhances the trial's potential impact. The move signifies a positive step forward in their clinical research efforts.
Read more →DTILPrecision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference
Precision BioSciences is set to participate in the 25th Annual Needham Virtual Healthcare Conference. The event will provide a platform for the company to discuss its advancements and strategies in the biopharma sector. Further details regarding their presentation and participation have not been disclosed.
Read more →DTIL▲ +12.1%on this news· ran to +37% by day 3
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update
Precision BioSciences has reported positive results from its fourth quarter and fiscal year 2025, highlighting the successful execution of the Phase 1 ELIMINATE-B trial for PBGENE-HBV. The trial has dosed 13 patients across the first five cohorts, demonstrating safety, tolerability, and promising antiviral activity. These findings were showcased in a Late Breaker presentation at AASLD, The Liver Meeting.
Read more →About Precision BioSciences, Inc.
Headquarters302 EAST PETTIGREW STREET, DURHAM, NC, 27701
BIOPHARMAWATCH ELITE PLUS
Trade the next DTIL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime